NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Kairos Pharma's Clinical Trials Arena Award for ENV-105 in Advanced Prostate Cancer
TL;DR
Kairos Pharma's award-winning ENV-105 offers investors a competitive edge by targeting treatment resistance in advanced prostate cancer with promising Phase 2 trial results.
Kairos Pharma's ENV-105 is a CD105-targeting monoclonal antibody that works by reversing drug resistance to restore effectiveness of standard cancer therapies in clinical trials.
Kairos Pharma's ENV-105 development addresses significant unmet medical needs in prostate cancer, potentially improving treatment outcomes and quality of life for patients worldwide.
Kairos Pharma won a 2025 Clinical Trials Arena award for ENV-105, a first-in-class antibody targeting CD105 to overcome cancer treatment resistance in ongoing trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Kairos Pharma Ltd. (NYSE American: KAPA) has been named a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer for its work on ENV-105.
ENV-105 (carotuximab) is a first-in-class CD105-targeting monoclonal antibody developed by Kairos Pharma to address treatment resistance in metastatic castration-resistant prostate cancer by targeting CD105, a protein identified as a key driver of resistance to various cancer treatments.
The award recognizes the company's work advancing ENV-105, including positive interim safety and efficacy results from a Phase 2 randomized clinical trial evaluating ENV-105 in combination with apalutamide for metastatic castration-resistant prostate cancer.
ENV-105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, aimed at addressing significant unmet medical needs in these cancer types.
ENV-105 aims to reverse drug resistance by targeting CD105, which elevates in response to standard therapy and causes resistance and disease relapse, thereby restoring the effectiveness of standard therapies across multiple cancer types.
Kairos Pharma is based in Los Angeles, California, and is a clinical-stage biopharmaceutical company focused on cancer therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer.
The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA.
Kairos Pharma received the 2025 Clinical Trials Arena Excellence Awards Research and Development Award for Advanced Prostate Cancer.
The Phase 2 clinical trial is specifically evaluating ENV-105 for metastatic castration-resistant prostate cancer, which is an advanced form of prostate cancer that no longer responds to hormone therapy.
Curated from InvestorBrandNetwork (IBN)
